Discounted Cash Flow Rating

Sell

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Omeros Corporation (OMER)

Pharmaceutical Preparations

https://www.omeros.com

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

201 ELLIOTT AVENUE WEST
SEATTLE, WA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/08/2009

Market Cap

238,451,494

Shares Outstanding

62,870,000

Weighted SO

62,865,491

Total Employees

N/A

Upcoming Earnings

08/14/2024

Similar Tickers

CRNX --.--%

ENTA --.--%

FOLD --.--%

CERE --.--%

CNTB --.--%

LGND --.--%

PASG --.--%

ORIC --.--%

LYEL --.--%

Beta

1.4520

Last Div

0.0000

Range

0.92-5.68

Chg

-0.1300

Avg Vol

380948

Mkt Cap

238451494

Exch

NASDAQ

Country

US

Phone

206 676 5000

DCF Diff

3.1437

DCF

-0.0037

Div Yield

0.0000

P/S

174.5619

EV Multiple

-3.6696

P/FV

-1.9137

Div Yield %

0.0000

P/E

-1.7026

PEG

0.0033

Payout

0.0000

Current Ratio

3.4120

Quick Ratio

3.4120

Cash Ratio

0.0356

DSO

10085.5966

DIO

0.0000

Op Cycle

10085.5966

DPO

2915.5160

CCC

7170.0807

Gross Margin

0.4041

Op Margin

-136.2438

Pretax Margin

-136.1728

Net Margin

-102.5205

Eff Tax Rate

0.2482

ROA

-0.3930

ROE

2.3851

ROCE

-0.6270

NI/EBT

0.7529

EBT/EBIT

0.9995

EBIT/Rev

-136.2438

Debt Ratio

1.2032

D/E

-3.4409

LT Debt/Cap

1.4464

Total Debt/Cap

1.4097

Int Coverage

101.3114

CF/Debt

-0.3621

Equity Multi

-2.8597

Rec Turnover

0.0362

Pay Turnover

0.1252

Inv Turnover

0.0000

FA Turnover

0.0723

Asset Turnover

0.0038

OCF/Share

-2.6791

FCF/Share

-2.6841

Cash/Share

2.7425

OCF/Sales

-113.6435

FCF/OCF

1.0019

CF Coverage

-0.3621

ST Coverage

-6.2077

CapEx Coverage

-537.1522

Div&CapEx Cov

-537.1522

P/BV

-1.9137

P/B

-1.9137

P/S

174.5619

P/E

-1.7026

P/FCF

-1.5332

P/OCF

-1.5360

P/CF

-1.5360

PEG

0.0033

P/S

174.5619

EV Multiple

-3.6696

P/FV

-1.9137

DPS

0.0000

Latest Headlines (EST)

Zacks Investment Research Jan 09, 20:01 Brian's Big Idea on Biotech Zacks Investment Research Jan 09, 20:01 Brian's Big Idea on Biotech Zacks Investment Research Jan 09, 20:01 Brian's Big Idea on Biotech Zacks Investment Research Jan 09, 20:01 Brian's Big Idea on Biotech Benzinga Nov 21, 06:30 Insiders Buying Taysha Gene Therapies And 3 Other Stocks Under $2

Revenue Product Segmentation